|
|
|
|
| LEADER |
01787nam a2200349 u 4500 |
| 001 |
EB001999821 |
| 003 |
EBX01000000000000001162722 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Tran, Khai
|
| 245 |
0 |
0 |
|a Quetiapine for major depressive disorder
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Khai Tran, Charlene Argáez
|
| 246 |
3 |
1 |
|a Quetiapine for MDD
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, January 30, 2020
|
| 300 |
|
|
|a 1 PDF file (43 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Quetiapine Fumarate / therapeutic use
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Depressive Disorder, Major / drug therapy
|
| 653 |
|
|
|a Antipsychotic Agents
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Guidelines as Topic
|
| 700 |
1 |
|
|a Argáez, Charlene
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK562922
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The aim of this report is to review the comparative clinical effectiveness and costeffectiveness of quetiapine versus other competing interventions such as typical antipsychotics, other atypical antipsychotics, lithium, lamotrigine, and antidepressants for the treatment of adults with MDD. This report also aims to identify evidence-based guidelines regarding the use of quetiapine for MDD.
|